Navigation Links
Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
Date:9/19/2007

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released detailed data from completed studies comparing the in vitro activity of its lead antibiotic drug candidate, oritavancin, to that of other antibiotics against a variety of susceptible and resistant strains of gram- positive bacteria. Results are being presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL. All posters highlighted below are being presented at 12:15 pm CDT.

Poster E-1617 is entitled "In Vitro Activity Profile of Oritavancin (ORI) Against Resistant Staphylococcal Populations From a Recent Surveillance Initiative." In this study, researchers examined clinical isolates of Staphylococcus aureus (n=5,008) and coagulase-negative staphylococci (n=862) collected in 2005-2006 from hospital sites in the U.S., Europe and Israel. Oritavancin was active against all staphylococcal isolates, including those with specific resistance phenotypes and including multi-drug resistant S. aureus, which were resistant to three or more of the following agents: ciprofloxacin, clindamycin, erythromycin, gentamicin, oxacillin, quinupristin- dalfopristin, trimethoprim-sulfa, vancomycin, daptomycin, and linezolid. Results from this study demonstrated that oritavancin had potent in vitro activity against a wide spectrum of staphylococci likely to be encountered in a variety of clinical settings.

Poster E-1613, entitled "In Vitro Activity Profile of Oritavancin (ORI) Against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents," compared the activity of oritavancin to vancomycin and teicoplanin against a diverse collection of staphylococci and enterococci, including strains with elevated MICs to linezolid, daptomycin, and/or vancomycin, as well as strains of streptococci. Bacterial isolates included S. aureus (n=35), coagulase-negative staphylococci (n=21), Enterococcus faecalis (
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... New to Antiretroviral Therapy Respond ... Similarly to Men and ... once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease inhibitor Kaletra(R) ... amount of HIV-1),and improving the immune system (increasing CD4 cells) ...
... a,biopharmaceutical company engaged in the discovery and development ... announced today,that Genentech, a collaborator, has moved a ... into a phase 1 clinical trial,that has begun ... and tolerability of both single and multiple doses ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:7/10/2014)... 11, 2014 Karen Middleton, Executive Director ... CEO of Planned Parenthood of the Rocky Mountains (PPRM), ... Udall and Representative Diana DeGette were in Washington, DC ... Lobby decision and keeping bosses out of women’s birth ... to the president today in Denver addressing issues related ...
(Date:7/10/2014)... The Capital Institute for Neurosciences at ... procedure in a clinical trial that delivers chemotherapy to ... , During the procedure, done at Capital Health Medical ... threaded a tiny catheter through the patient’s femoral artery ... and into the brain. Once the catheter reached the ...
(Date:7/10/2014)... 3 fatty acids had healthier joints than those fed ... acids, according to Duke Medicine researchers. , The findings, ... (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that unhealthy ... to worsening osteoarthritis. , "Our results suggest that dietary ... in the link between obesity and osteoarthritis," said Farshid ...
(Date:7/10/2014)... More than 200 experts on aggression, who ... violence, will attend the 21st World Meeting of the ... at the Loews Atlanta Hotel, July 15-19. , ... meeting, which is held every other year on alternating ... leading scholars from more than 20 different countries, which ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... account for an increasing number of accidents in ... in Safety Reboot. The articles highlight safety issues ... estimated 317 million accidents occur on the job ... Three features continue to explore "preventable workplace accidents." ...
Breaking Medicine News(10 mins):Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3
... the Black Death as the world's worst pandemic if the ... get life prolonging drugs. The illness has killed 25 million ... infected each day with HIV, which destroys the immune system. ... will die, pushing the death toll beyond the 40 million ...
... suffer from asphyxia, which can lead to brain injury, multiple ... cent of babies who suffer from a moderate lack of ... no effective treatments to reduce the risk of asphyxia at ... a baby's temperature may have beneficial effects. ,UK researchers ...
... in the alpha gene are the cause of premature menopause ... about 2% of the total population. ,The University of ... of a genetic test, which would allow women// with a ... at risk. They analysed DNA from women who had experienced ...
... undergoing coronary artery bypass surgery is rising, even though ... artery bypass surgery uses a blood vessel from another ... or clogged arteries in the heart. A buildup of ... known as atherosclerosis. ,In the new study, ...
... FDA issued a statement about the potential for depression and ... reports say that the 15-year-old pilot who crashed his plane ... investigators don't know whether or not the teen, Charles J. ... death. Blood tests should reveal if the drug was in ...
... from the Institute of Health Sciences in Oxford found that ... likely to have a stillbirth, or to develop pre-eclampsia.// Taking ... the researchers. ,The researchers reviewed more than 23 ... benefits of anti-platelet drugs, of which low-dose aspirin is the ...
Cached Medicine News:
ThermalSeal RT (5mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates. Will not wrinkle in the freezer....
DMSO-resistant microplate sealing film...
Sealing tape featuring 3M adhesive technology. Opaque and strong. Prevents photo-degradation....
Aluminum Seal, Reflective, Bulk...
Medicine Products: